Evaluating therapeutic efficacy against cancer stem cells: New challenges posed by a new paradigm
Evaluating therapeutic efficacy against cancer stem cells: New challenges posed by a new paradigm
复制标题
DOI：
10.1016/j.stem.2007.10.005
复制
发表时间：
2007-11-01
期刊：
影响因子：
23.9
通讯作者：
Wang, Jean C. Y.
中科院分区：
文献类型：
--
作者：
Wang, Jean C. Y.
目前抗癌药物功效的测量反映了大量细胞杀伤，并且不太适合检测针对维持肿瘤生长的癌症干细胞（CSC）的活性。CSC范式需要重新检查用于评价抗癌治疗临床疗效的方法，以及临床前药物开发期间采用的策略。
Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.